NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia


  • Neuclone plans for the onset of P-I clinical study for NeuLara, a Stelara’s biosimilar evaluating NeuLara vs the US & EU score of Stelara in healthy candidates in Australia under CTN scheme of TGA in H2’19
  • NeuLara is developed utilizing NeuMAX technology & Right from the Start development approach, analytically tested with X-ray crystallography for the confirmation of the identical structure b/w NeuLara and Stelara
  • J&J’s Stelara (ustekinumab) is a mAb targeting IL-12 and IL-23, approved for moderate to severe plaque psoriasis in adults and children aged ≥12yrs and has generated $5.2B revenue in 2018. NeuLara X-ray Crystallography is technique allowing 3-D imagining of complex molecules

Click here to read full press release/ article | Ref: PRNewsWire | Image: NeuClone